

# Angela Pirillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3807539/publications.pdf>

Version: 2024-02-01

109  
papers

5,502  
citations

117571

34  
h-index

85498

71  
g-index

110  
all docs

110  
docs citations

110  
times ranked

8045  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 721-729.	0.8	5
2	New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 161-166.	1.2	11
3	Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 829-831.	0.8	2
4	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. <i>Journal of the American Heart Association</i> , 2022, 11, e023668.	1.6	12
5	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. <i>Annals of Medicine</i> , 2022, 54, 1036-1046.	1.5	9
6	Insights from ORION studies: focus on inclisiran safety. <i>Cardiovascular Research</i> , 2021, 117, 24-26.	1.8	6
7	Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years. <i>Clinical Chemistry</i> , 2021, 67, 30-32.	1.5	5
8	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, 1033-1045.	1.8	33
9	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 1061.	1.8	23
10	Global epidemiology of dyslipidaemias. <i>Nature Reviews Cardiology</i> , 2021, 18, 689-700.	6.1	290
11	Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?. <i>Circulation</i> , 2021, 144, 183-185.	1.6	10
12	Lipoprotein remnants: to be or not to be. <i>European Heart Journal</i> , 2021, 42, 4844-4846.	1.0	4
13	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. <i>Current Atherosclerosis Reports</i> , 2021, 23, 79.	2.0	23
14	Recent insights into low-density lipoprotein metabolism and therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 120-126.	1.3	7
15	Statins increase Lp(a) plasma level: is this clinically relevant?. <i>European Heart Journal</i> , 2020, 41, 2285-2287.	1.0	14
16	Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. <i>Atherosclerosis</i> , 2020, 292, 90-98.	0.4	213
17	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <i>Current Atherosclerosis Reports</i> , 2020, 22, 74.	2.0	9
18	The cardiovascular benefit of Lp(a) reduction: not there yet. <i>European Heart Journal</i> , 2020, 41, 4256-4258.	1.0	3

#	ARTICLE	IF	CITATIONS
19	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020, 22, 24.	2.0	41
20	Beyond LDL-C levels, does remnant cholesterol estimation matter?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1088-1090.	0.8	8
21	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	8
22	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020, 42, e1-e5.	1.2	5
23	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
24	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
25	Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool. <i>Atherosclerosis Supplements</i> , 2020, 42, e65-e71.	1.2	8
26	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020, 42, e59-e64.	1.2	8
27	Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy. <i>Atherosclerosis Supplements</i> , 2020, 42, e25-e29.	1.2	1
28	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	1.8	63
29	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
30	Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. <i>Stroke</i> , 2019, 50, 1758-1765.	1.0	23
31	Cholesterol metabolism, pancreatic $\beta$ -cell function and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2149-2156.	1.8	76
32	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. <i>Pharmacological Research</i> , 2019, 143, 143-150.	3.1	25
33	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. <i>Current Opinion in Lipidology</i> , 2019, 30, 462-469.	1.2	18
34	Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 531-532.	0.8	5
35	Lipid Lowering and Incidence of Cataract, a Role for Fibrates. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 318-319.	2.3	1
36	High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?. <i>Cardiovascular Research</i> , 2019, 115, 6-7.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Biological Consequences of Dysfunctional HDL. <i>Current Medicinal Chemistry</i> , 2019, 26, 1644-1664.	1.2	65
38	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 12.	2.0	67
39	Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. <i>International Journal of Cardiology</i> , 2018, 252, 193-198.	0.8	34
40	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. <i>Cardiology Clinics</i> , 2018, 36, 241-256.	0.9	5
41	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.4	48
42	PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?. <i>European Heart Journal</i> , 2018, 39, 2586-2588.	1.0	10
43	Pitavastatin and HDL: Effects on plasma levels and function(s). <i>Atherosclerosis Supplements</i> , 2017, 27, e1-e9.	1.2	21
44	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017, 174, 3973-3985.	2.7	105
45	Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 396-406.	1.1	111
46	Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?. <i>Molecular Therapy</i> , 2017, 25, 2435-2437.	3.7	1
47	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
48	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	1.2	2
49	Effect of PCSK9 loss-of-function mutation R46I on plasma lipids, endothelial function and vascular inflammation in the post-prandial state. <i>Atherosclerosis</i> , 2017, 263, e136.	0.4	0
50	PCSK9 inhibition in statin-intolerant HeFH patients: What's new?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1525-1527.	0.8	0
51	Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. <i>Atherosclerosis</i> , 2017, 263, e262-e263.	0.4	4
52	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 343-351.	1.0	14
53	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016, 112, 429-442.	1.8	105
54	Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. <i>Current Medicinal Chemistry</i> , 2016, 23, 983-999.	1.2	29

#	ARTICLE	IF	CITATIONS
55	Statin Intolerance: Diagnosis and Remedies. <i>Current Cardiology Reports</i> , 2015, 17, 27.	1.3	32
56	Update on the management of severe hypertriglyceridemia &ndash; focus on free fatty acid forms of omega-3. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2129.	2.0	12
57	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	4.0	144
58	Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From inÂvitro evidence to clinical studies. <i>Atherosclerosis</i> , 2015, 243, 449-461.	0.4	231
59	HDL in Infectious Diseases and Sepsis. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 483-508.	0.9	145
60	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1489-1503.	0.9	94
61	HDL in innate and adaptive immunity. <i>Cardiovascular Research</i> , 2014, 103, 372-383.	1.8	236
62	15â€Lipoxygenaseâ€Mediated Modification of HDL<sub>3</sub> Impairs eNOS Activation in Human Endothelial Cells. <i>Lipids</i> , 2014, 49, 317-326.	0.7	9
63	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. <i>Contemporary Diabetes</i> , 2014, , 125-139.	0.0	2
64	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	2.0	12
65	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 751-759.	1.1	39
66	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 341-346.	0.8	23
67	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. <i>Atherosclerosis Supplements</i> , 2013, 14, 237-242.	1.2	27
68	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. <i>International Journal of Cardiology</i> , 2013, 170, S16-S20.	0.8	32
69	Prevalence of classical CD14 <sup>++</sup> /CD16 <sup>+</sup> but not of intermediate CD14 <sup>++</sup> /CD16 <sup>+</sup> monocytes in hypoalphalipoproteinemia. <i>International Journal of Cardiology</i> , 2013, 168, 2886-2889.	0.8	15
70	High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. <i>Cardiology</i> , 2013, 124, 116-125.	0.6	509
71	LOX-1, OxLDL, and Atherosclerosis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	1.4	548
72	Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases. <i>Disease Markers</i> , 2013, 35, 413-418.	0.6	60

#	ARTICLE	IF	CITATIONS
73	Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality. <i>Current Pharmaceutical Design</i> , 2013, 19, 3841-3857.	0.9	27
74	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. <i>Journal of the American Heart Association</i> , 2012, 1, 27-41.	1.6	114
75	Emerging role of high density lipoproteins as a player in the immune system. <i>Atherosclerosis</i> , 2012, 220, 11-21.	0.4	158
76	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophage LDLR levels. <i>Atherosclerosis</i> , 2012, 220, 381-386.	0.4	212
77	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 230-233.	1.0	23
78	Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. <i>PLoS ONE</i> , 2012, 7, e31086.	1.1	21
79	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. <i>Atherosclerosis</i> , 2011, 214, 331-337.	0.4	36
80	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2011, 22, 324-325.	1.2	1
81	HDLs, immunity, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2011, 22, 410-416.	1.2	41
82	Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1608-1619.	1.9	15
83	Dual effect of hypochlorite in the modification of high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 447-451.	1.0	10
84	The Challenge of Lipid Management in Patients with Diabetes or Other Endocrine Disorders. <i>European Endocrinology</i> , 2010, 7, 92.	0.8	0
85	The 15-Lipoxygenase-Modified High Density Lipoproteins 3 Fail to Inhibit the TNF- $\alpha$ -Induced Inflammatory Response in Human Endothelial Cells. <i>Journal of Immunology</i> , 2008, 181, 2821-2830.	0.4	24
86	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 925-931.	1.1	137
87	Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. <i>Cardiovascular Research</i> , 2007, 75, 566-574.	1.8	18
88	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. <i>Atherosclerosis</i> , 2007, 191, 265-271.	0.4	131
89	15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 292-300.	1.2	34
90	Modified HDL: Biological and physiopathological consequences. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 371-386.	1.1	75

#	ARTICLE	IF	CITATIONS
91	In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. <i>International Journal of Molecular Medicine</i> , 2006, 17, 203-8.	1.8	27
92	Proteome of endothelial cell-derived procoagulant microparticles. <i>Proteomics</i> , 2005, 5, 4443-4455.	1.3	85
93	Native LDL and Oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF- $\kappa$ B, CRE dependent pathway and affect PGE2 synthesis. <i>International Journal of Molecular Medicine</i> , 2004, 14, 353-9.	1.8	15
94	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. <i>British Journal of Haematology</i> , 2004, 127, 97-104.	1.2	53
95	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. <i>Cardiovascular Research</i> , 2003, 59, 169-180.	1.8	59
96	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. <i>Biochemical Journal</i> , 2002, 362, 627.	1.7	25
97	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. <i>Biochemical Journal</i> , 2002, 362, 627-634.	1.7	37
98	Overexpression of Inducible Heat Shock Protein 70 in COS-1 Cells Fails to Protect From Cytotoxicity of Oxidized LDLs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 348-354.	1.1	18
99	Oxidized Lipoproteins and Endothelium. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 155-60.	1.4	16
100	Enhanced Macrophage Uptake of Elastase-Modified High-Density Lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2000, 271, 386-391.	1.0	13
101	Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells. <i>FEBS Letters</i> , 1999, 462, 113-116.	1.3	11
102	3.P.87 Two distinct components of oxidized LDL mediate the heat shock response and cytotoxicity triggered by OxLDL. <i>Atherosclerosis</i> , 1997, 134, 216-217.	0.4	0
103	Simvastatin Modulates the Heat Shock Response and Cytotoxicity Mediated by Oxidized LDL in Cultured Human Endothelial Smooth Muscle Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 231, 437-441.	1.0	30
104	Human Endothelial Cells Exposed to Oxidized LDL Express hsp70 Only When Proliferating. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1104-1111.	1.1	29
105	Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells. <i>Medical Science Symposia Series</i> , 1996, , 603-612.	0.0	0
106	Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. <i>Journal of Lipid Research</i> , 1996, 37, 1-14.	2.0	60
107	Oxidized lipoproteins induce long-lasting inhibition of nitric oxide synthase from a murine endothelioma cell line (bEnd.4). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 123-130.	1.5	2
108	Oxidized LDL induce hsp70 expression in human smooth muscle cells. <i>FEBS Letters</i> , 1995, 372, 1-5.	1.3	34

#	ARTICLE	IF	CITATIONS
109	Constituents of <i>Nothapodytes foetida</i> . <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1995, , 583.	0.9	22